Impact of caffeine on myocardial perfusion reserve assessed by semiquantitative adenosine stress perfusion cardiovascular magnetic resonance.
Adenosine
/ administration & dosage
Aged
Caffeine
/ administration & dosage
Coronary Circulation
/ drug effects
Female
Humans
Hyperemia
Magnetic Resonance Imaging, Cine
Male
Middle Aged
Myocardial Ischemia
/ diagnostic imaging
Myocardial Perfusion Imaging
/ methods
Predictive Value of Tests
Prospective Studies
Purinergic P1 Receptor Antagonists
/ administration & dosage
Reproducibility of Results
Vasodilation
/ drug effects
Vasodilator Agents
/ administration & dosage
Adenosine stress CMR
Caffeine
Ischemia
MPRI
Myocardial perfusion reserve
Splenic switch-off
Journal
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance
ISSN: 1532-429X
Titre abrégé: J Cardiovasc Magn Reson
Pays: England
ID NLM: 9815616
Informations de publication
Date de publication:
24 06 2019
24 06 2019
Historique:
received:
19
12
2018
accepted:
20
05
2019
entrez:
25
6
2019
pubmed:
25
6
2019
medline:
29
1
2020
Statut:
epublish
Résumé
Adenosine is used in stress perfusion cardiac imaging to reveal myocardial ischemia by its vasodilator effects. Caffeine is a competitive antagonist of adenosine. However, previous studies reported inconsistent results about the influence of caffeine on adenosine's vasodilator effect. This study assessed the impact of caffeine on the myocardial perfusion reserve index (MPRI) using adenosine stress cardiovascular magnetic resonance imaging (CMR). Moreover, we sought to evaluate if the splenic switch-off sign might be indicative of prior caffeine consumption. Semiquantitative perfusion analysis was performed in 25 patients who underwent: 1) caffeine-naïve adenosine stress CMR demonstrating myocardial ischemia and, 2) repeat adenosine stress CMR after intake of caffeine. MPRI (global; remote and ischemic segments), and splenic perfusion ratio (SPR) were assessed and compared between both exams. Global MPRI after caffeine was lower vs. caffeine-naïve conditions (1.09 ± 0.19 vs. 1.24 ± 0.19; p < 0.01). MPRI in remote myocardium decreased by caffeine (1.24 ± 0.19 vs. 1.49 ± 0.19; p < 0.001) whereas MPRI in ischemic segments (0.89 ± 0.18 vs. 0.95 ± 0.23; p = 0.23) was similar, resulting in a lower MPRI ratio (=remote/ischemic segments) after caffeine consumption vs. caffeine-naïve conditions (1.41 ± 0.19 vs. 1.64 ± 0.35, p = 0.01). The SPR was unaffected by caffeine (SPR 0.38 ± 0.19 vs. 0.38 ± 0.18; p = 0.92). Caffeine consumption prior to adenosine stress CMR results in a lower global MPRI, which is driven by the decreased MPRI in remote myocardium and underlines the need of abstinence from caffeine. The splenic switch-off sign is not affected by prior caffeine intake.
Sections du résumé
BACKGROUND
Adenosine is used in stress perfusion cardiac imaging to reveal myocardial ischemia by its vasodilator effects. Caffeine is a competitive antagonist of adenosine. However, previous studies reported inconsistent results about the influence of caffeine on adenosine's vasodilator effect. This study assessed the impact of caffeine on the myocardial perfusion reserve index (MPRI) using adenosine stress cardiovascular magnetic resonance imaging (CMR). Moreover, we sought to evaluate if the splenic switch-off sign might be indicative of prior caffeine consumption.
METHODS
Semiquantitative perfusion analysis was performed in 25 patients who underwent: 1) caffeine-naïve adenosine stress CMR demonstrating myocardial ischemia and, 2) repeat adenosine stress CMR after intake of caffeine. MPRI (global; remote and ischemic segments), and splenic perfusion ratio (SPR) were assessed and compared between both exams.
RESULTS
Global MPRI after caffeine was lower vs. caffeine-naïve conditions (1.09 ± 0.19 vs. 1.24 ± 0.19; p < 0.01). MPRI in remote myocardium decreased by caffeine (1.24 ± 0.19 vs. 1.49 ± 0.19; p < 0.001) whereas MPRI in ischemic segments (0.89 ± 0.18 vs. 0.95 ± 0.23; p = 0.23) was similar, resulting in a lower MPRI ratio (=remote/ischemic segments) after caffeine consumption vs. caffeine-naïve conditions (1.41 ± 0.19 vs. 1.64 ± 0.35, p = 0.01). The SPR was unaffected by caffeine (SPR 0.38 ± 0.19 vs. 0.38 ± 0.18; p = 0.92).
CONCLUSION
Caffeine consumption prior to adenosine stress CMR results in a lower global MPRI, which is driven by the decreased MPRI in remote myocardium and underlines the need of abstinence from caffeine. The splenic switch-off sign is not affected by prior caffeine intake.
Identifiants
pubmed: 31230593
doi: 10.1186/s12968-019-0542-7
pii: 10.1186/s12968-019-0542-7
pmc: PMC6589875
doi:
Substances chimiques
Purinergic P1 Receptor Antagonists
0
Vasodilator Agents
0
Caffeine
3G6A5W338E
Adenosine
K72T3FS567
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
33Références
Int J Cardiol. 2018 Feb 1;252:229-233
pubmed: 29196090
J Nucl Med. 2004 May;45(5):730-8
pubmed: 15136619
J Am Coll Cardiol. 2011 Jan 4;57(1):70-5
pubmed: 21185504
Circulation. 2002 Jan 29;105(4):539-42
pubmed: 11815441
Curr Trends Clin Med Imaging. 2018;2(3):
pubmed: 30976755
Nutrients. 2018 Aug 13;10(8):
pubmed: 30104545
J Cardiovasc Magn Reson. 2010 Jul 21;12:42
pubmed: 20663155
Magn Reson Med. 2004 Aug;52(2):296-9
pubmed: 15282811
Int J Cardiovasc Imaging. 2017 Nov;33(11):1753-1759
pubmed: 28547666
Int J Cardiovasc Imaging. 2018 Apr;34(4):625-632
pubmed: 29177579
J Magn Reson Imaging. 2013 Apr;37(4):865-74
pubmed: 23335425
J Nucl Med. 1995 Nov;36(11):2016-21
pubmed: 7472591
J Magn Reson Imaging. 2004 Jul;20(1):39-45
pubmed: 15221807
JACC Cardiovasc Imaging. 2017 May;10(5):526-537
pubmed: 28412420
J Invasive Cardiol. 2014 Nov;26(11):580-5
pubmed: 25363999
Pharmacol Toxicol. 1995 Feb;76(2):93-101
pubmed: 7746802
N Engl J Med. 1978 Jan 26;298(4):181-6
pubmed: 339084
J Am Coll Cardiol. 2006 Jan 17;47(2):405-10
pubmed: 16412869
Radiology. 2013 Mar;266(3):759-65
pubmed: 23238157
J Am Coll Cardiol. 2006 Jun 6;47(11):2296-302
pubmed: 16750699
J Cardiovasc Magn Reson. 2015 Nov 05;17:94
pubmed: 26541808
J Am Coll Cardiol. 2001 Jan;37(1):109-16
pubmed: 11153724
Circulation. 2003 Jul 29;108(4):432-7
pubmed: 12860910
J Am Coll Cardiol. 2006 Apr 18;47(8):1630-8
pubmed: 16631001
J Am Coll Cardiol. 2018 Mar 6;71(9):969-979
pubmed: 29495996
J Nucl Cardiol. 2012 Jun;19(3):474-81
pubmed: 22302182
J Cardiovasc Magn Reson. 2017 Jan 13;19(1):1
pubmed: 28081721
Int J Cardiovasc Imaging. 2019 Apr;35(4):675-682
pubmed: 30426300
Circulation. 1993 May;87(5):1698-704
pubmed: 8491025
Clin Physiol Funct Imaging. 2015 Jan;35(1):49-56
pubmed: 24418159
J Magn Reson Imaging. 2007 Jun;25(6):1131-5
pubmed: 17520736
J Am Coll Cardiol. 2008 Dec 9;52(24):2008-16
pubmed: 19055993
Eur Heart J Cardiovasc Imaging. 2017 Nov 1;18(11):1216-1221
pubmed: 28329392
Pharmacol Biochem Behav. 1997 Nov;58(3):721-6
pubmed: 9329065
J Cardiovasc Magn Reson. 2017 Dec 18;19(1):103
pubmed: 29254482
Radiology. 2015 Sep;276(3):732-40
pubmed: 25923223